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INTRODUCTION
The World Health Report 2000: Health Systems: Improving 
Performance (WHO 2000); the World Health Organization 
(WHO) resolution on sustainable health financing, uni-
versal health coverage, and social health insurance (WHO 
2005); and the World Health Report: Health Systems 
Financing: The Path to Universal Coverage (WHO 2010) all 
highlighted the substantial economic burden faced by 
individuals with no access to affordable, high-quality 
health care. These reports placed the need to address the 
economic effect of illness— in particular, catastrophic and 
impoverishing health expenditure—on the global health 
policy agenda.
Financial protection—a core element of universal 
health coverage—aims to ensure that people receive the 
health care services they require without facing finan-
cial ruin (WHO 2010). Devising strategies to protect 
populations from financial risk has become a major 
focus of global health policy development (WHO and 
World Bank 2014).
Affordable access to high-quality health care is now 
considered a basic human right and a critical step to 
the achievement of sustainable economic and social 
development and the elimination of poverty (Sustainable 
Development Solutions Network 2014; WHO 2015). 
This imperative is reflected in the third Sustainable 
Development Goal, which sets a target for achieving uni-
versal health coverage, including financial risk protection; 
access to high-quality essential health care services; and 
access to safe, effective, high-quality, and affordable essen-
tial medicines and vaccines for all (UN General Assembly 
2015). This commitment is echoed in the World Bank’s 
recent call to eradicate impoverishment owing to health 
care expenditures by 2030 (Kim 2014).
A lack of both prepayment mechanisms and the means 
and resources to pool risks has limited the capacity of 
many health care systems to provide access to high-quality 
health care services. As a result, for decades, many health 
systems, particularly in low- and middle-income coun-
tries (LMICs), have relied heavily on private payments in 
the form of out-of-pocket costs to fund health care. 
In 2014, 18 percent of total health expenditure globally 
came from out-of-pocket payments (WHO 2014). The 
burden is even greater in LMICs. In 2014, out-of-pocket 
payments equaled approximately 39 percent of total 
health expenditure for low-income countries, 56 percent 
for lower-middle-income countries, and 30 percent for 
upper-middle-income countries (WHO 2016).
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Relying on out-of-pocket costs to finance health care 
is both inefficient and inequitable and places a major 
financial strain on individuals and households (WHO 
2010). Out-of-pocket costs can perpetuate poverty and 
lead many individuals to delay or forgo necessary care 
(Peters and others 2008; van Doorslaer and others 2006). 
This link, where the household’s investment in health 
further impoverishes that household, can lead to a con-
tinuous cycle of poor health and poverty (Knaul, Wong, 
and Arreola-Ornelas 2012).
This burden is of particular concern for persons with 
chronic diseases, for whom repeated and lifelong costs 
are associated with the management and treatment of 
illness (Kankeu and others 2013). For example, in some 
countries, a household may have to pay as much as eight 
days’ worth of wages to purchase one month’s supply of 
only one of the multiple medicines required for the opti-
mal treatment of cardiovascular disease (CVD) or diabe-
tes (Cameron and others 2009; Gelders and others 2006). 
In more extreme cases, the costs of treatment for chronic 
and long-term conditions such as human immunodefi-
ciency virus/acquired immune deficiency syndrome 
(HIV/AIDS) and surgery for some cancers have kept 
patients confined to hospitals indefinitely pending pay-
ment to the hospitals or forced them to stop treatment 
altogether (Human Rights Watch 2006). Although 
households, even those that are already impoverished, 
may be able to manage a one-time shock and recover in 
the short run (for example, over a period of a week or a 
month), they may not be able to withstand the ongoing 
costs of treatment for chronic diseases.
Furthermore, LMICs are undergoing a protracted 
epidemiological transition (Frenk and others 1989). 
Underfunded and weak health systems continue to face 
a backlog of acute diseases and conditions associated 
with poverty, together with the onslaught of costly and 
chronic noncommunicable diseases (NCDs), conditions 
that affect the entire population at all income levels. This 
situation inevitably results in competing priorities about 
which services to include in essential packages of care 
and which to cover through national insurance funds 
(Beaglehole and others 2011). However, evidence is lack-
ing on the household-level economic burden associated 
with certain categories of disease, particularly chronic 
diseases. Such evidence would inform global health pol-
icy development by highlighting where the greatest gains 
in financial protection might be realized (Shrime and 
others 2015) and help governments prioritize the mea-
sures needed to move toward universal health coverage.
This chapter estimates the burden of catastrophic 
health expenditure (CHE) associated with chronic ill 
health and injuries in LMICs and describes the broader 
economic effects on households. It is organized as follows. 
We begin by estimating the population-level burden of 
CHE—the most common indicator of the household 
economic burden of health expenditure—and draw on 
empirical research of specific chronic diseases and injuries 
to estimate the prevalence of CHE associated with seven 
categories of conditions: cancers, CVDs, chronic infec-
tious diseases, endocrine diseases, injuries, renal diseases, 
and respiratory diseases. We then draw on a review of 
NCDs in LMICs to describe the broader household eco-
nomic effects associated with ill health, including impov-
erishing health expenditure, productivity effects, distressed 
financing, and treatment discontinuation. We discuss 
implications of the results for improving financial protec-
tion and offer directions for future research.
POPULATION-LEVEL ESTIMATES OF 
CATASTROPHIC AND IMPOVERISHING 
HEALTH EXPENDITURES
Catastrophic and impoverishing health expenditures, 
also referred to as medical impoverishment, continue to 
challenge health systems around the world and pose a 
key barrier to improving economic and social well-being 
(Knaul, Wong, and Arreola-Ornelas 2012). Very conser-
vative estimates suggest that, globally, at least 150 million 
people a year face financial catastrophe and 100 million 
are driven into poverty by expenditure on health care 
(Xu and others 2007).
CHE and impoverishing health expenditure are inter-
related, but distinct, concepts (figure 6.1). Consensus 
is lacking on the definition of what constitutes a 






A.  Health care expenditure is defined as catastrophic using any of the
     conventional definitions.
B.  Impoverishing health expenditure results at any level of expenditure:
       •     Darker shaded area: for the population already in poverty,
               any level of spending further entrenches social disadvantage,
               and there is a high likelihood of forgoing care.
C.  Health care expenditure is catastrophic and impoverishes
     the household.
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catastrophic level of expenditure for households and 
the most appropriate denominator for measuring CHE: 
expenditure, income, or consumption (Knaul, Wong, 
and Arreola-Ornelas 2012; O’Donnell and others 2007). 
Box 6.1 distinguishes between these two concepts.
The economic burden associated with ill health 
extends beyond paying for care (table 6.1). Household 
members cope with the onset of illness in various ways, 
and the response can influence their treatment-seeking 
behavior (McIntyre and others 2006; Okoli and Cleary 
2011; Sauerborn, Adams, and Hien 1996; Xu and others 
2007). When faced with ill health, particularly unex-
pected events, the household must mobilize resources to 
pay for health care, often by borrowing money, using 
limited savings, and selling assets—all of which can neg-
atively affect the long-term economic well-being of the 
household, including its ability to deal with ongoing 
health care needs and future health shocks (Kruk, 
Goldmann, and Galea 2009; McIntyre and others 2006; 
Peters and others 2008; Russell 2004). Ill health can also 
affect the productivity of both the sick individual and a 
family caregiver, leading to loss of paid employment or 
educational opportunities. All these factors severely 
impair the family’s capacity to earn income in both 
temporary and longer-term ways.
Financial protection through tax-financed social 
health insurance programs is a major pillar of efforts 
by national governments to achieve universal health 
coverage. Indeed, there is evidence of the extent to 
which health insurance–based measures effectively 
provide financial protection by curbing the burden of 
medical expenditure (Essue and others 2015; 
Knaul, Arreola-Ornelas, and Méndez-Carniado 2016). 
Although progress has been made at a population 
level, research shows variations in the financial 
protection afforded to different subgroups (box 6.2). 
Box 6.1
Conceptual Relationship between Catastrophic 
Health Expenditure and Impoverishing Health 
Expenditure
Conceptually, catastrophic health expenditure is a measure 
of the burden of health care expenditure (that is, out-of-
pocket costs) on a household’s available resources. It can 
result from sizable and unpredictable one-off payments 
and from a steady flow of unbudgeted medical bills, includ-
ing relatively small payments (Knaul and others 2006; 
Schoenberg and others 2007; Thuan and others 2006).
Impoverishing health expenditure is defined as expendi-
ture on health care that results in a household falling below 
the prevailing poverty line or deepening its impoverish-
ment if it is already poor (Knaul, Wong, and Arreola-
Ornelas 2012; Xu 2005). Such impoverishment is also 
linked to employment, because loss of income owing to ill 
health can drive households into poverty (Gertler and 
Gruber 2002).
Table 6.1 Indicators Used to Measure the Household Economic Burden of Ill Health
Indicator Definition Advantages Limitations
Catastrophic health 
expenditure
Total health care expenditure (out-of-pocket 
costs) as a percentage of household 
resources (O’Donnell and others 2007; Xu and 
others 2003). The denominator, household 
resources, is measured as discretionary 
expenditure (also referred to as capacity to 
pay or nonfood expenditure), total expenditure, 
or household income.
• Provides objective measure 
of the drain on available 
household resources caused 
by health care expenditure
• Is the most commonly 
used indicator and widely 
endorsed
• Has wide variation in the threshold and 
denominator used and the categories of 
health care expenditure included, which 
makes it difficult to use as a benchmark 
across studies
• Does not capture forgone care owing to 
unaffordable health care costs
• Arbitrary threshold: implicitly assumes that 
the given level of expenditure will impose 




to as medical 
impoverishment)
The outcome when total health care 
expenditure subtracted from baseline income 
results in the household’s income falling below 
the prevailing poverty line (Wagstaff and van 
Doorslaer 2003)
• Provides a measure of 
the effect of illness on 
the household’s economic 
well-being and potentially 
the national economy
• Does not account well for the 
poorest households, for whom any 
level of expenditure further entrenches 
their poverty
table continues next page
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Table 6.1 Indicators Used to Measure the Household Economic Burden of Ill Health (continued)
Indicator Definition Advantages Limitations
Economic hardship 
or financial stress
A measure of the potential consequences for 
the household of health care expenditure. It 
captures instances in which the household is 
unable to meet the costs of essential payments 
(housing, food, heating, child care, transport, 
health care). It is most commonly defined as 
an instance of missing any one of the specified 
payments (Essue and others 2011).
• Takes account of the 
opportunity costs 
associated with health care 
expenditure and potential 
economic consequences for 
households
• Has wide variation in the definition and 
categories of expenses included, which 
limits its generalizability
• Does not account well for instances in 
which households were unable to meet 
essential bills before the onset of illness
• Tends to be measured in cross-sectional 
studies, which are unable to assess 
the effect and recurrence of these 
consequences over time
Distressed financing A measure of the strategies used by the 
household to pay for health care expenses, 
often including savings, borrowed funds 
(either through formal or informal loan or 
through credit schemes), or sale of assets. It 
is a descriptive measure that accounts for the 
percentage of households using each of the 
financing strategies (Kruk, Goldmann, and Galea 
2009; McIntyre and others 2006).
• Accounts for the economic 
consequences of health care 
expenditure for household 
economies
• Offers insights into 
potentially effective informal 
strategies for dealing with 
health care costs
• Has wide variation in the distressed 
financing categories included, which limits 
its generalizability
• Tends to be measured in cross-sectional 
studies, which are unable to assess the 
effect of using these strategies over time
Box 6.2
Monitoring Universal Health Coverage: Achieving Financial Protection in Asia
Universal health coverage entails everyone having 
access to needed health services without financial 
hardship. In the Western Pacific region, several coun-
tries have made progress toward achieving universal 
health coverage and protecting their populations 
from financial risk.
Country-specific studies on the equity of health 
service use and financial protection have been 
conducted in Mongolia (Tsilaajav, Nanzad, and 
Ichinnorov 2015), the Philippines (Ulep and dela 
Cruz 2013), and Vietnam (Minh and Phuong 
2016). These studies examined health service use, 
out-of-pocket health expenditures, catastrophic 
health expenditure, impoverishing health expendi-
ture, and their determinants over time. Data were 
from nationally representative surveys—socio-
economic or income and expenditure surveys—
containing information on health service use and 
health expenditure. The method used to calculate 
out-of-pocket, catastrophic, and impoverishing 
health expenditure followed the WHO methodol-
ogy in all four countries (Xu 2005).
Annual household out-of-pocket health expendi-
tures ranged from US$144 in Mongolia to US$190 
in Vietnam. Medicines were a major component of 
out-of-pocket health expenditures in Mongolia and 
the Philippines. The average proportion of house-
holds that incurred catastrophic health expendi-
ture (CHE) ranged from 0.9 percent in Mongolia 
to 2.3 percent in Vietnam (figure B6.2.1). Across 
expenditure quintiles, the proportion of house-
holds that incurred CHE increased in Mongolia 
and the Philippines but decreased in Vietnam as 
the expenditure quintile increased. Over time, 
the proportion of households incurring CHEs 
increased in the Philippines, but it fell in Mongolia 
and Vietnam.
Impoverishment resulting from health expenditures 
was highest in the lowest and second-to-lowest 
box continues next page
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expenditure quintiles, with Vietnam at 6.4 percent 
and Mongolia at 2.3 percent in the lowest expendi-
ture quintile (figure B6.2.2).
Given differences in the data sources, methods, recall 
periods, and survey years, there are limitations com-
paring results across countries. However, these coun-
try-specific studies offer evidence for monitoring the 
effects of universal health coverage, including health 
service use and financial protection. Further research 
and cross-country comparisons should focus on 
examining the shock and cumulative effects of the 
burden of health payments, particularly for poor 
and vulnerable populations and for households with 
members who are aging or have chronic diseases, 
where the effect of these outcomes is likely greater.
Box 6.2 (continued)
Figure B6.2.1 Proportion of Households with 
Catastrophic Health Expenditure in Selected Asian 
Countries, by Expenditure Quintile, Various Years
Sources: Tsilaajav, Nanzad, and Ichinnorov 2015, based on data from the 2012 
Mongolia Household Socio-Economic Survey; Ulep and dela Cruz 2013, based 
on data from the 2012 Philippines Family and Income Expenditure Survey; 















































Figure B6.2.2 Proportion of Households Impoverished 
Owing to Health Expenditures in Selected Asian 
Countries, by Expenditure Quintile, Various Years
Sources: Tsilaajav, Nanzad, and Ichinnorov 2015, based on data from the 2012 
Mongolia Household Socio-Economic Survey; Ulep and dela Cruz 2013, based on 
data from the 2012 Philippines Family and Income Expenditure Survey; Minh and 
Phuong 2016, based on data from the 2014 Vietnam Living Standards Survey.
Note: For the Philippines, the national average proportion of impoverishment owing 


























































The poorest quintile of populations and older adults 
continue to be at greater risk than the general popula-
tion (Goeppel and others 2016).
Much of the work in this field has focused on des-
cribing the burden associated with catastrophic and 
impoverishing health expenditure at the population 
level, illuminating the problem, and mobilizing support 
for population-wide initiatives such as universal health 
coverage. A limitation of the research to date is its use 
of population-based data that lack detailed indicators of 
the health status, including specific diseases, of individu-
als in the households under study. Research on the eco-
nomic burden associated with particular diseases is 
needed to understand how specific diseases, especially 
those that are chronic, affect the economic well-being 
of households.
Population-based estimates of CHE using data 
from household surveys have been found to vary sub-
stantially from research in populations with chronic 
diseases. For instance, in Vietnam, population-level 
surveys found that 2.3 percent of all households had 
CHE in 2014 (box 6.2), whereas studies of individuals 
with diabetes (Smith-Spangler, Bhattacharya, and 
Goldhaber-Fiebert 2012), acute myocardial infarction 
(Jan and others 2016), and HIV/AIDS (Tran and 
 others 2013) found that 8 percent, 38 percent, 
and 35 percent, respectively, had CHE. In China, 
population-level surveys found that 13 percent of all 
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households had CHE in 2008 (Y. Li and others 2012), 
whereas studies of individuals with stroke (Heeley and 
others 2009), diabetes (Smith-Spangler, Bhattacharya, 
and Goldhaber-Fiebert 2012), and acute myocardial 
infarction (Jan and others 2016) found that 71 percent, 
80 percent, and 15 percent, respectively, had CHE. This 
difference between population-level and disease- 
related estimates of CHE has also been found in both 
high- income countries (Essue and others 2011; Essue 
and others 2014; Schoen and others 2010) and other 
LMICs (Huffman and others 2011; Saito and others 
2014; Xu and others 2003).
The household economic burden of ill health is not 
simply a population-level problem; it is also highly 
influenced by the disease course of individual condi-
tions. Understanding variations in outcomes within 
populations can help decision makers identify the 
highest-risk populations, account for the ways in which 
 different conditions affect patients and their house-
holds, and generate economic incentives for preventing 
and managing disease.
PREVALENCE ESTIMATES OF CATASTROPHIC 
HEALTH EXPENDITURE ASSOCIATED 
WITH CHRONIC ILL HEALTH AND INJURIES 
IN LMICS
This section analyzes the prevalence of CHE related to 
chronic ill health and injuries in LMICs and the way it 
differs among regions. The analysis is based on a system-
atic search of studies that reported rates of CHE associ-
ated with the treatment and management of seven 
conditions:
• Cancers: Breast, uterine, cervical, colorectal, mouth, 
pharynx, ovarian, stomach and tracheal, and bron-
chial or lung
• CVDs: CVD (undefined), angina, heart disease, acute 
coronary syndrome, acute myocardial infarction, 
stroke, cerebrovascular disease (undefined), and 
ischemic heart disease
• Chronic infectious diseases: HIV/AIDS, malaria, 
tuberculosis, and hepatitis B
• Endocrine diseases: Diabetes and endocrine disease 
(undefined, but not diabetes)
• Injuries: Injuries caused by assault, blunt objects, 
burns, falls, road traffic accidents, and sharp objects
• Renal diseases: Chronic kidney disease and kidney 
disease (undefined).
• Respiratory diseases: Asthma, chronic obstructive pul-
monary disease, and pulmonary disease (undefined).
We initially included maternal, infant, and childhood 
conditions and mental illnesses in the search, but 
excluded them from the analysis, because too few studies 
reported rates of CHE for these conditions. From a 
broader perspective, the remaining seven categories of 
disease constitute almost 60 percent of the total global 
burden of disease, as shown in table 6.2.
Methodology
This discussion is based on a systematic search of studies 
that reported rates of CHE associated with the treatment 
and management of chronic ill health and injuries. The 
detailed search strategy and the equations used for the 
calculations are described in online annex 6A, along with 
the characteristics of the studies identified in the search.
One issue that arose is the lack of consensus in the 
measurement of CHE. A commonly used approach is to 
measure the household’s total annual expenditure on 
health care or health-related expenses (for example, 
transport) as a proportion of the household’s resources, 
measured in terms of income, expenditure, or consump-
tion (O’Donnell and others 2007). Household resources 
as the denominator in this equation may involve a 
measure of either nondiscretionary expenditure 
(Wagstaff and van Doorslaer 2003) or capacity to pay 
(Xu and others 2003), both of which define CHE in 
terms of nonfood expenditure. In this analysis, we note 
the CHE definitions and thresholds used in each study 
but nonetheless include each as essentially the same out-
come when calculating the prevalence of CHE associated 
with each condition.
Summary of Findings
The systematic search identified 41 studies (42 published 
papers) that reported rates of disease-related CHE. 
Table 6.2 Global Burden of Disease, by Category of 
Disease, 2012
Disease category











a. Measured using disability-adjusted life year.
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Most studies used a cross-sectional design (30), recruit-
ing either a convenience sample (22) or a random 
sample (18) from either a health care facility or a 
hospital (26) or from households in the community 
(14); 1 study used administrative data. The studies 
were conducted between 1997 and 2013, with 14 con-
ducted between 2010 and 2013. Of these 41 studies, 
7 were conducted in high-income countries (2 in 
Australia, 1 in Greece, 2 in the Republic of Korea, 
and 2 in the United States). This analysis focuses only 
on LMICs.
Most of the studies were conducted in middle- income 
countries, clustered in South and East Asia; the greatest 
numbers were conducted in China (8) and India (6) 
(map 6.1). Endocrine diseases and CVDs were the most 
studied conditions (table 6.3), which is reasonably con-
sistent with the 20 leading causes of disease burden 
(Global Burden of Disease Study 2013 Collaborators 
2015). Data coverage from the systematic search was best 
for countries in the upper-middle-income group; the 
greatest gaps were for research on renal and respiratory 
diseases (see online annex 6A, table 6A.4).
Map 6.1 Density of Studies on Disease-Related Catastrophic Health Expenditure 
Note: The map includes studies found for all country income categories. For multicountry studies, each country is represented in the fi gure so the total number of studies depicted 
exceeds the number of studies identifi ed in the systematic search.
1 20
Number of records
Table 6.3 Density of Conditions for the Study of Disease-Related Catastrophic Health Expenditure, 




Endocrine diseases 7 17 10
Cardiovascular diseases 5 9 7
Cancers 1 5 5
table continues next page
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All studies collected data on out-of-pocket payments 
for direct medical expenses, although the categories of 
expenses collected varied somewhat. Where specified, 
most studies collected data on medicines (30), and more 
than half collected data on hospitalizations (24) and 
medical consultations (27). Nonmedical costs (travel, 
accommodation, care expenses) were taken into account 
in 19 studies and lost productivity in 4 studies.
CHE was most commonly measured in terms of a 
household’s capacity to pay, defined as total expenditure net 
of food expenses (Xu and others 2003), followed by income 
thresholds and total expenditure (figure 6.2). By condition 
category, the ranges in CHE rates were as follows:
• Cancers: 6.2 percent (cancer, undefined, Republic of 
Korea) to 67.9 percent (cancer, undefined, the Islamic 
Republic of Iran)
• CVDs: 0.05 percent (heart disease, Nepal) to 84.3 
percent (CVD, Tanzania)
• Chronic infectious diseases: 7.1 percent (malaria, 
South Africa) to 90.0 percent (HIV/AIDS, the Lao 
People’s Democratic Republic)
• Endocrine diseases: 1.0 percent (diabetes, Nepal) to 
26.6 percent (diabetes, Ecuador)
• Injuries: 0.8 percent (injury, undefined, Nepal) to 
46 percent (road traffic injury, India).
• Maternal, infant, and childhood conditions: 1.0 percent 
(rotavirus, Malaysia) to 44.8 percent (rotavirus, Bolivia)
• Mental illnesses: 5.5 percent (depressive disorders, India)
• Renal diseases: 9.8 percent (kidney disease, the 
United States) to 71.0 percent (chronic kidney dis-
ease, Australia)
• Respiratory diseases: 3.0 percent (asthma, Myanmar) 
to 46.0 percent (chronic obstructive pulmonary dis-
ease, Australia).
Rates of CHE from studies based on samples from 
hospitals or health care facilities were significantly higher 
than those from studies based on samples from house-
holds or communities for each World Bank income 
category (low-income: x−diff, 56.2; t = 5.00, p = 0.007; 
lower-middle-income: x−diff, 27.1; t = 4.97, p < 0.0001; 
upper-middle-income: x−diff, 26.5; t = 3.75, p < 0.0001). 
This difference is not surprising, because hospitals are 
not an unbiased source of population data on health 
expenditure.
Overall, across all LMICs, the largest population 
experiencing CHE comprised persons with renal dis-
eases (187.7 million), followed by CVDs (138.4 million), 
chronic infectious diseases (101.9 million), endocrine 
diseases (46.0 million), cancers (14.3 million), respira-
tory diseases (9.6 million), and injuries (0.9 million). In 
upper-middle-income countries, the largest population 
experiencing CHE comprised persons with renal diseases 
(100.6 million), followed by CVDs (78.2 million), 
chronic infectious diseases (74.2 million), endocrine 
diseases (22.4 million), cancers (11.9 million), respira-
tory diseases (8.2 million), and injuries (0.5 million). 
In lower-middle-income countries, the largest popula-
tion experiencing CHE comprised persons with renal 
diseases (83.3 million), followed by CVDs (59.9 million), 
endocrine diseases (23.3 million), and chronic infectious 
diseases (6.2 million). In low-income countries, chronic 
infectious diseases were associated with the greatest bur-
den of CHE (21.4 million), followed by renal diseases 
(3.8 million), CVDs (0.4 million), and endocrine dis-
eases (0.3 million) (figure 6.3).
In a sensitivity analysis, we calculated the populations 
with CVD-related CHE using only studies that measured 
CHE defined as health care expenditures in excess of 
40 percent of the household’s capacity to pay. We found 
Table 6.3 Density of Conditions for the Study of Disease-Related Catastrophic Health Expenditure, 




Chronic infectious diseases 3 4 6
Injuries 1 2 —
Maternal, infant, and childhood 
conditions
— 2 1
Renal diseases — — 1
Respiratory diseases — 1 —
Mental illnesses — 1 —
Multiple conditions — — 1
Note: The number in each cell is the count of studies of each condition identifi ed in the review. Some studies included multiple conditions and different countries, and thus the total 
count in this table exceeds the total number of articles reviewed. — = none.
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Note: For most studies, capacity to pay was defi ned as in Xu and others (2003). Different data were used to calculate the denominator for each catastrophic health expenditure (CHE) outcome 
(capacity to pay, income, total expenditure), so standardizing the estimates to a common benchmark was not possible. Each threshold of CHE was used to denote an event of catastrophic 
signifi cance for the individual patient or household under investigation. Because they are linked through a common conceptual construct and as a way to allow for comparisons of the burden of 
CHE across the range of diseases, the varying thresholds used in each study are noted here but are treated as essentially the same outcome in this analysis. The CHE rate of 100 percent, reported 
for renal replacement therapy in Thailand (Prakongsai and others 2009), was excluded from the calculation of the case catastrophe rate for renal diseases.
Figure 6.2 Catastrophic Health Expenditure Rates, by Source and Disease Category
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no significant difference in case catastrophe rates and the 
prevalence of CVD-related CHE for all regions when 
the analysis was limited to studies using this common 
definition (table 6.4).
Figure 6.4 summarizes the case catastrophe rate rela-
tive to the prevalence of each category of condition. 
The case catastrophe rate is the population-weighted 
average CHE rate for each condition and World Bank 
income category. The large estimated burden of CHE 
predicted to be associated with renal diseases is explained 
by the high prevalence of disease and the high case 
catastrophe rate in populations with prevalent disease; 
renal diseases affect many individuals and are associated 
with a high burden because of the type of care required. 
Those circumstances also apply to chronic infectious 
diseases and CVDs. The case catastrophe rate for injuries 
is lower in low-income countries than in the other 
 country income groups, despite the high prevalence of 
 injuries. This variation is in contrast to cancers, where 
the prevalence of disease is relatively lower, so the main 
driver of the prevalence of cancer-related CHE is the 
high case catastrophe rate associated with the treatment 
and management of these conditions in all national 
income groups.
OTHER MEASURES OF HOUSEHOLD-LEVEL 
ECONOMIC EFFECT OF CHRONIC ILL HEALTH 
AND INJURIES IN LMICS
In this section, we report data from a review of the 
disease-related burden associated with indicators other 
than CHE: impoverishing health expenditure, produc-
tivity effects, distressed financing, and treatment discon-
tinuation (table 6.1). These indicators supplement and 
complement the measurement of CHE, because they 
help describe the effect of ill health on a household’s 
economic well-being (Moreno-Serra, Millett, and Smith 
2011; Ruger 2012), including the way households 
respond, opportunity costs, and the effect of forgone 
income. The indicators also tend to focus on the effect of 
ill health on the poorest of the poor, who may be omitted 
from other measures, including CHE, because their 
income is so low.
We did not estimate the disease-related prevalence 
associated with each indicator, as done for CHE, given 
insufficient data. We thus restrict this discussion to a 
descriptive analysis. The populations affected by these 
other measures are not mutually exclusive, so there is 
significant overlap with the population estimates of 
disease-related CHE reported in the previous section.
A systematic review of 47 LMIC studies was conducted 
to evaluate the household economic effect of NCDs. 
Figure 6.3 Estimated Population with Catastrophic Health 
Expenditures Related to Chronic Ill Health and Injuries, by Disease 



















Chronic infectious diseases 
Table 6.4 Sensitivity Analysis: Comparison of Case Catastrophe Rates and the Projected Population with 
Cardiovascular Disease–Related Catastrophic Health Expenditure
Country 
income level
All definitions of CHEa
Definition limited to CHE as > 40% of 









Low 8.1 162,163 6.6 131,398
Lower-middle 21.2 22,065,683 21.0 21,829,842
Upper-middle 51.9 78,153,956 46.9 70,665,614
Note: CHE = catastrophic health expenditure; CVD = cardiovascular disease.
a. Catastrophic health expenditure was defi ned as (a) more than 40 percent of household capacity to pay (or nonfood expenditure); (b) more than 10 percent of household 
expenditure; (c) more than 40 percent of effective income; or (d) more than 30 percent of household income in the published studies.
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Figure 6.4 Rate of Catastrophic Health Expenditure Relative to Average Prevalence of Each Condition, 
by Country Income Group
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The methods are described in annex 6B. The systematic 
review synthesized evidence from studies in populations 
of patients with NCDs. Of the 47 studies identified, 
11 overlapped with the studies identified in the previously 
described systematic search. CHE was the most com-
monly measured outcome. However, several studies also 
incorporated additional indicators of the economic bur-
den of NCDs on households.
Impoverishing Health Expenditure
Although impoverishing health expenditure is now rou-
tinely investigated in many population-based studies, 
including alongside CHE, few studies have investigated 
the disease-related burden. In the review of NCD studies 
in LMICs, seven studies measured the rate of NCD-related 
impoverishing health expenditure. Across the studies, the 
rate of impoverishment was below 15 percent. However, 
in a study conducted among Chinese people experienc-
ing hypertension, stroke, or coronary heart disease, the 
incidence of impoverishment hovered around 50 percent 
and was not statistically different after implementation 
of the national health insurance scheme (J. Wang and 
others 2012; figure 6.5).
Productivity Changes
Six studies examined the effect of chronic diseases, 
particularly CVDs, on an individual’s capacity to 
maintain usual working status. In some settings, more 
than 80 percent of patients affected by CVDs reported 
having to limit their usual work activities and more 
than 60 percent reported having to work less. In addi-
tion to the effect on individuals’ productivity, one 
study conducted across four countries also found that 
family members had to increase their work activities 
or find new work. Whether such changes in productiv-
ity are different for households that are experiencing 
disease than for those that are not is unclear. For 
instance, a study conducted in India found that the 
decreases in workforce participation of individuals 
experiencing angina were not significantly different 
from those of households not experiencing disease 
(Alam and Mahal 2014).
By contrast, a study by Zhang, Chongsuvivatwong, 
and Geater (2006) found that the presence of major 
chronic illness resulted in a 6.5 percent decrease in the 
probability of remaining in paid work in China. Similarly, 
although the workforce participation rates of cancer- 



























































Note: The blue stacks correspond to the left-hand axis and illustrate the weighted case catastrophe rate (%) for each condition, in each country income category. The blue line 
corresponds to the right-hand axis and illustrates the average weighted prevalence of each condition, in each country income category. The t-bars illustrate the 95 percent 
confi dence intervals for the weighted case catastrophe rates, in cases where they could be calculated.
Figure 6.4 (continued)
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of non-cancer-affected households, when an individual 
with cancer was removed from consideration, there were 
no discernible differences between households with and 
without disease. In spite of this finding, although the 
incidence of work-related changes was captured, very 
few studies valued these changes in monetary terms 
(figure 6.6).
Distressed Financing
Six studies attempted to quantify the financing strate-
gies used to pay for health care for NCDs, including 
CVDs and cancers. Whereas in one study, almost all 
households relied on savings to finance their health care 
(Bhojani and others 2013), more commonly, households 
reported selling assets or calling on family and friends. 
This circumstance was especially evident in the most 
socioeconomically disadvantaged households (Huffman 
and others 2011). The few studies that compared house-
holds with and without disease found that these strate-
gies were needed more often in households confronted 
with chronic disease (Alam and Mahal 2014; figure 6.7).
Treatment Discontinuation
An obvious consequence of unaffordable health care is 
treatment attrition or abandonment (Arora, Eden, and 
Pizer 2007; Israels and others 2008; Jan and others 2015). 
For example, in a study of CVD patients in Argentina, 
China, India, and Tanzania, up to 99 percent of households 
reported not taking CVD medications because of the cost 
(Huffman and others 2011). Similarly, in a study con-
ducted among diabetes-affected households across 35 
LMICs, less than 30 percent of individuals were in posses-
sion of medications in 71 percent of countries (Smith-
Spangler, Bhattacharya, and Goldhaber-Fiebert 2012). This 
outcome was not routinely examined within studies of 
NCD-related CHE. The relationship between CHE and 
treatment discontinuation is important for discerning 
whether trends in health care expenditure, and CHE in 
particular, have been affected by the discontinuation or 
avoidance of necessary health care by households or indi-
viduals when faced with unaffordable costs. This is highly 
relevant for the treatment of chronic conditions in cases 
where treatment attrition or abandonment can lead to 
further deterioration of health and higher health care costs.
Figure 6.5 Proportion of Households with Noncommunicable Diseases Experiencing Impoverishing Health Expenditure, 
by Disease Category and Country Income Group
Note: BFB = the proportion of households was calculated using the basic food basket method as the threshold; CVD = cardiovascular disease; NCD = noncommunicable disease; 
OECD = the proportion of households was calculated using the Organisation for Economic Co-operation and Development defi nition for poverty as the threshold. The t-bars illustrate 
the 95 percent confi dence intervals for the estimate (percentage of households), in cases where they could be calculated.
a. Statistically signifi cant difference was found between those with and those without disease.
b. No statistically signifi cantly difference was found between those with and those without disease
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Figure 6.6 Proportion of Households with Noncommunicable Diseases Reporting Productivity Effects, by Disease Category and 
Country Income Group
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Note: CVD = cardiovascular disease. The t-bars illustrate the 95 percent confi dence intervals for the estimate (percentage of households), in cases where they could be calculated.
DISCUSSION
Patients with chronic conditions and injuries in LMICs 
face a substantial economic burden as a result of paying 
for health care. Chronic conditions such as renal, cardio-
vascular, and endocrine diseases account for the largest 
populations with CHE. However, in low-income coun-
tries individuals with chronic infectious diseases such 
as HIV/AIDS, tuberculosis, and malaria are the largest 
populations with CHE.
The factors underlying these estimates are both preva-
lence of disease and rates of CHE associated with each 
category of conditions. For example, the comparatively 
higher burden associated with renal conditions in all set-
tings is likely explained by the fact that renal disease is an 
end product of other NCDs, notably diabetes and CVDs. 
These precursory NCDs are undertreated (Khatib and 
others 2016; Lange and others 2004; W. Li and others 2016), 
and the costs associated with treating renal disease are 
high, including the costs of medicines and dialysis 
(Teerawattananon and others 2016; White and others 2008).
The high costs of treatment for different conditions 
are due to factors such as place of treatment and out-of-
pocket costs for different types of treatment. For exam-
ple, out-of-pocket costs associated with hospitalization 
for an acute event may be high, as for conditions such 
as stroke in China (Heeley and others 2009) and acute 
myocardial infarction in both China and India (Jan and 
others 2016). However, paying for treatment that is 
required on an ongoing basis can also lead to a high 
cost burden, whether the payments are marginal, such 
as paying for medicines or, at a more extreme end, the 
cost of regular dialysis for managing chronic kidney 
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disease (Prakongsai and others 2009; Ramachandran 
and Jha 2013).
Endocrine diseases and injuries in low-income set-
tings both have relatively high prevalence but compara-
tively lower rates of CHE. For injuries, although the costs 
associated with treating an acute episode in either a 
hospital or a community health setting may be high, 
ongoing health care costs after recovery may be minimal. 
However, if the severity of the injury affects the 
individual’s ability to continue in paid work, the house-
hold may still experience negative economic conse-
quences from this loss of income, which is not captured 
in the CHE measures. In addition, in low-income coun-
tries, survival rates from injuries such as those resulting 
from traffic accidents are lower (Dalal and others 2013), 
so the risk of incurring CHE is lower.
HIV/AIDS, like other long-term illnesses, is associated 
with a relatively higher rate of CHE, likely because of the 
ongoing costs of medicines in settings where access to 
free antiretroviral treatment is suboptimal. For cancers, 
the prevalence of disease is relatively lower, both overall 
and in each country income category, but the cost burden 
is comparatively high because of treatment costs associ-
ated with chemotherapy, radiation, and surgery (Aggarwal 
and Sullivan 2014; Pramesh and others 2014).
In the context of an increasing prevalence of multiple 
morbidity, estimated at 7.8 percent in LMICs (Afshar and 
others 2015), such high levels of expenditure associated 
Figure 6.7 Proportion of Households with Noncommunicable Disease Using Distressed Financing Strategies, by Disease Category and 
Country Income Group
Note: CVD = cardiovascular disease; NCD = noncommunicable disease. The t-bars illustrate the 95 percent confi dence intervals for the estimate (percentage of households), in cases where 
they could be calculated.
a. Statistically signifi cant difference was found between those with and those without disease.
b. No statistically signifi cantly difference was found between those with and those without disease.
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with one condition would potentially compromise an 
individual’s ability to afford the range of care that is 
required when faced with multiple morbidity. This cir-
cumstance could lead to trade-offs, including a prioriti-
zation of treatment for acute conditions over chronic 
care, especially in cases where conditions are asymptotic.
There is substantial variation in the cost burden 
and risk of CHE associated with chronic conditions and 
injuries in cases where expenditures are often repeated 
and continuous. Curbing the rates of CHE will require 
targeting financial risk protection to cover elements of 
treatment for conditions with high risk of CHE and high 
prevalence, such as renal diseases and CVDs. In low- 
income settings, additional protection might be required 
for major infectious diseases. Identifying the elements of 
treatment that impose the greatest cost burden, which 
may be common across various disease categories, will 
help achieve the greatest gains in mitigating the risk of 
CHE at a population level.
Global work, especially from the WHO, has high-
lighted the significant household economic burden that is 
associated with accessing and using health care services, 
particularly in LMICs. In addition, it has been a driving 
force in efforts to implement effective financial protection 
mechanisms to mitigate this burden. Comparability of 
our results with WHO global estimates of the prevalence 
of CHE depends on the relative distribution of chronic dis-
eases, injuries, and comorbidity within the population-level 
data used to generate the estimates. The rates of CHE are 
much higher when measured in the population with dis-
ease than in the population as a whole. Our analysis, 
which uses samples of persons with disease, shows that 
many more people in LMICs and globally are at risk of 
CHE than previously estimated (Xu and others 2007). 
Furthermore, the estimates reported here for each cate-
gory of conditions are not cumulative, given the high 
prevalence of multiple morbidity overall and the overlap-
ping of comorbid conditions between disease categories 
included in this analysis.
LIMITATIONS OF THE RESEARCH
Comparability among Countries and Health Care 
System Contexts
The economic burden associated with health care expenses 
is context specific. Differences in the financing and service 
provision arrangements among health care systems in 
each country may influence the populations and the 
breadth of services covered, the mix of private and pub-
licly funded services, and the out-of-pocket costs associ-
ated with health care use. In addition, despite advances in 
evidence-based medicine and its contribution toward 
mitigating variations in health care practice among set-
tings, the disease-specific treatment options that are avail-
able and that constitute best practice may vary among 
(and within) countries. These differences ultimately 
influence the generalizability and interpretation of the 
individual estimates.
Differences in Measurement of CHE
The studies consulted measured CHE using different 
definitions, thresholds, and categories of expenditure 
included as out-of-pocket costs, different data sources, 
and different recall periods, which potentially intro-
duced measurement error. However, the findings from a 
sensitivity analysis indicated that our results were robust 
despite the combining of varied estimates.
Differences in Quality and Breadth of Evidence
Given the lack of comprehensive evidence on the level 
of CHE in different populations, estimates for one set-
ting sometimes were based on data extrapolated from 
studies conducted in other settings. In cases where data 
on the prevalence of CHE for any particular country 
income category were missing, we applied a conserva-
tive strategy of using the estimate from the next-highest 
income category. In addition, the results describe the 
relative burden of disease-related CHE between condi-
tions and country-income categories but not the poten-
tial distributional burden within the populations in 
each category.
Much of the evidence on the disease-related burden 
of CHE is from cross-sectional studies that lack a control 
group and cannot capture repeat expenditures, so they 
are limited in their ability to attribute CHE directly to 
the disease or injuries. In addition, the smaller, clinic-
based studies may not be fully representative of the 
population with disease in each country. Despite their 
limitations, these studies are the sole source of evidence 
and provide a starting point from which to investigate 
differences in the burden of CHE among different 
categories of chronic conditions.
The evidence also tends to come from smaller studies 
of cohorts recruited from hospitals or health care facili-
ties, which can lead to higher estimates of health care 
expenditure than those based on community or house-
hold samples (Lavado, Brooks, and Hanlon 2013; Raban, 
Dandona, and Dandona 2013). Hospital expenses may 
explain some of this difference, because the samples in 
hospitals are a biased (nonrandom) sample of the 
population. Moreover, household samples were asked to 
report costs associated with previous hospitalizations, 
which suggests that recall bias may be stronger in 
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the community-based studies than in the clinic- or 
hospital-based studies.
POLICY DIRECTIONS FOR IMPROVING 
FINANCIAL PROTECTION
As the epidemiological transition progresses over the 
next few decades, the double burden of infectious dis-
eases and NCDs will continue to challenge health care 
systems in LMICs, which will be confronted with caring 
for older and more costly populations. Catastrophic and 
impoverishing health expenditure will increase globally 
unless action is taken to offer deeper packages of finan-
cial protection that include the treatment of chronic 
disease and injury. In formulating measures to address 
this issue, policy makers focus on universal health cover-
age, which aims to provide population-wide protection 
through various social health protection mechanisms. 
However, given severe resource constraints, such pro-
grams are often able to provide only limited protection 
of certain diseases and treatments; achieving compre-
hensive financial protection will inevitably be a long-
term goal. The design of the package of entitlements and 
covered services should take into account both the pop-
ulations most at risk and the diseases and conditions that 
drive catastrophic and impoverishing health expenditure. 
Country examples exist of how to implement this 
through progressive universalism (Gwatkin and Ergo 
2011; Jamison and others 2013); one example, about 
which much has been written, is the catastrophic expen-
diture fund of Mexico’s Seguro Popular (Knaul, Arreola-
Ornelas, and Méndez-Carniado 2016).
In this study, we identify significant variation in the 
household economic burden by condition. The high 
burden observed for many chronic conditions such as 
renal diseases indicates potential areas where targeted 
programs could be developed to address the populations 
currently experiencing the greatest financial burden. 
These results suggest that universal health coverage 
should be developed as part of a multipronged strategy 
that addresses not only system-level drivers of the 
household economic burden but also disease-specific 
drivers. For individual diseases, basic packages should 
include specific interventions that are shown to be 
effective—for example, low-cost dialysis (Liyanage and 
others 2015) and polypill treatments for CVD (Webster 
and Rodgers 2016) as well as disease management and 
prevention strategies.
The research on disease-related CHE tends to be clus-
tered in areas that do not necessarily reflect the diseases 
that have the greatest burden and largest household 
economic effect. Under-researched areas such as mental 
illness should not be overlooked when developing strat-
egies to improve financial risk protection.
This study has important implications for the design 
of benefit packages. The conventional approach has 
been to place cost-effectiveness or best buys as the over-
riding consideration in designing benefit packages 
(Chisholm and others 2012; Evans and Etienne 2010; 
WHO and World Economic Forum 2011). The rationale 
for this approach is strong: given severe resource con-
straints, priority needs to be given to funding programs 
that deliver the greatest health outcomes for the dollar. 
However, although this approach promotes the objec-
tive of health maximization, it does not directly address 
the problem that such benefit packages are designed to 
address—that is, financial protection. This study pro-
vides evidence to guide policy makers in the design of 
benefit packages and entitlements. It demonstrates the 
need to prioritize the relative financial burden across 
disease areas and in different settings to ensure cover-
age of the disease-specific health care and health- 
related services that are most associated with 
catastrophic and impoverishing health expenditure 
(Jamison and others 2013).
This research also highlights the need for an ongoing 
focus on and investment in prevention. The most effec-
tive way to reduce disease-related CHE is to prevent such 
conditions. This prevention is particularly critical in 
LMICs, where the double burden of infectious diseases 
and NCDs continues to place a major strain on 
health care systems. Evidence from the extended cost- 
effectiveness literature has demonstrated the gains to be 
made in strengthening financial protection through 
investment in prevention. Public financing of programs 
such as vaccination for human papillomavirus infection 
and management of risk factors, such as obesity for 
diabetes and hypertension for CVD, have been shown to 
have the potential to curb catastrophic and impoverish-
ing health expenditure significantly, thereby enhancing 
financial protection across populations (Levin and 
others 2015; Verguet and others 2015).
Addressing the factors that lead to and perpetuate 
entrenched poverty will also produce the greatest gains 
in mitigating the economic burden of chronic ill health 
experienced by households. Rates of catastrophic and 
impoverishing health expenditure should decline over 
time as universal health coverage is implemented along-
side other poverty reduction strategies, including efforts 
to meet the Sustainable Development Goals. These 
efforts should reduce the burden of disease overall and 
improve the capacity of households to access and use 
required health care services. In monitoring progress, 
including the effect of efforts to reach the Sustainable 
Development Goals, priority should be given to 
138 Disease Control Priorities: Improving Health and Reducing Poverty
evaluating changes in financial protection among the 
population as a whole as well as within subgroups 
most at risk of catastrophic and impoverishing health 
expenditure.
FUTURE RESEARCH DIRECTIONS
More prospective longitudinal studies are needed to 
examine the extent to which households can recover 
from the burden of catastrophic and impoverishing 
health expenditure. These types of studies, although few, 
have helped identify the determinants of recovery from 
an illness shock as well as factors that potentially 
enhance resilience to such shocks (Essue and others 
2012; Heeley and others 2009; Jan and others 2015; Jan 
and others 2016; Kimman and others 2015). Prospective 
studies will also help distinguish between the effect and 
consequences of one shock versus cumulative expendi-
ture as well as the potential for health interventions to 
improve household economic circumstances (Essue and 
others 2014; Kuper and others 2010).
Longitudinal research is also needed to monitor 
progress in mitigating CHE and impoverishing health 
expenditure. Monitoring progress using different cross-
sections of population data over time cannot account 
well for the fact that new households may encounter 
CHE, while others may become nonspenders because 
they are no longer able to pay for care. Therefore, 
declines over time do not necessarily mean that health 
care has become more affordable for all.
Furthermore, the long-term effect on households of 
impoverishing health expenditure, distressed financing 
arrangements, changes in workforce participation, and 
treatment discontinuation are poorly understood. More 
multidimensional assessments of the household eco-
nomic burden of chronic ill health are needed using 
routinely measured indicators along with CHE and 
impoverishing health expenditure (Moreno-Serra, Millet, 
and Smith 2011; Ruger 2012). Such studies would sup-
port the design of financial protection programs and 
improve the targeting of interventions, because these 
indicators provide greater insights into the effect of illness 
and health care expenditure on the household economy.
More research is needed to understand the link back 
to health. Although the effect of the social determinants 
of health is well understood (Friel and Marmot 2011), 
longer-term cohort studies are needed to assess how 
these economic consequences perpetuate the cycle of 
chronic ill health and social disadvantage (van Doorslaer 
and others 2006). Evidence on the link between the eco-
nomic burden of disease, health outcomes, and social 
disadvantage would strengthen the economic case for 
improving access to affordable care.
CONCLUSIONS
In this chapter, we estimate the economic burden associ-
ated with seven categories of chronic conditions as well as 
injuries. We find that most CHE is due to renal, cardiovas-
cular, and chronic infectious diseases and that the global 
burden of CHE is much higher than previously estimated.
Meeting the global commitment to enhance financial 
protection of populations, including the World Bank’s 
goal of eliminating impoverishing health expenditure 
by 2030, requires a concerted effort to address the main 
drivers of CHE in all settings. In designing financial 
protection programs, policy makers need to give prior-
ity to covering populations and conditions associated 
with the greatest economic burden. Furthermore, 
needed health care services still remain out of reach for 
millions with disease who live in poverty. Strategies to 
enhance financial protection need to be implemented 
alongside broader poverty alleviation efforts, which 
collectively will generate the greatest gains in mitigating 
the household-level economic burden of chronic ill 
health globally.
ANNEXES
The annexes to this chapter are as follows. They are avail-
able at http://www.dcp-3.org/DCP.
• Annex 6A. Description of Data Sources and Search 
Strategy.
• Annex 6B. Search Strategy for Prospectively Designed 
Studies of Household Economic Effect of Chronic 
Disease.
NOTE
World Bank Income Classifications as of July 2014 are as 
follows, based on estimates of gross national income 
(GNI) per capita for 2013:
• Low-income countries (LICs) = US$1,045 or less
• Middle-income countries (MICs) are subdivided:
(a) lower-middle-income = US$1,046 to US$4,125
(b) upper-middle-income (UMICs) = US$4,126 to US$12,745
• High-income countries (HICs) = US$12,746 or more.
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